Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Vedolizumab |
| Trade Name | Entyvio |
| Synonyms | LDP-02|MLN02 |
| Drug Descriptions |
Entyvio (vedolizumab) is a monoclonal antibody that targets alpha4beta7 integrin and blocks interaction with MAdCAM-1, thereby preventing endothelial binding and extravasation of leukocytes (PMID: 27003961, PMID: 32472970). |
| DrugClasses | |
| CAS Registry Number | 943609-66-3 |
| NCIT ID | C95798 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cyclophosphamide + Tacrolimus + Vedolizumab | Cyclophosphamide Tacrolimus Vedolizumab | 0 | 0 |
| Ipilimumab + Nivolumab + Vedolizumab | Ipilimumab Nivolumab Vedolizumab | 0 | 1 |
| Vedolizumab | Vedolizumab | 0 | 0 |